Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors : Baselga J, Im SA, Iwata H, Cortés J, De Laurentiis M, Jiang Z, Arteaga CL, Jonat W, Clemons M, Ito Y, Awada A, Chia S, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Takahashi M, Vuylsteke P, Hachemi S, Dharan B, Di Tomaso E, Urban P, Massacesi C, Campone M
Year : 2017
Journal : Lancet Oncol
Volume : 18(7)
Pages : 904-916

Guidance for the prevention and treatment of venous thromboembolism in cancer patients

Authors : Awada A, Baurain JF, Clement P, Hainaut P, Holbrechts S, Hougardy JM, Jochmans K, Mathieu V, Mebis J, Strijbos MH, Vulsteke C, Verheij M
Year : 2016
Journal : Belgian J Medical Oncology
Volume : 7(6)
Pages : 217-23

The Future of Access to Innovative Medicines in Cancer Therapy: Towards Conditional Dialogue Fostering Affordable Therapeutic Innovation

Authors : van Dyk N, De Greve J, Schots R, Awada A, Van Eycken L, Geldof T
Year : 2016
Journal : Vlerick business school
Volume : 7
Pages : -

Progressive multifocal leukoencephalopathy mimicking cerebral metastases in a patient treated for nasopharyngeal carcinoma

Authors : Oualla K, Aoun F, Lemort M, Harrouk A, Latifyan S, Awada A, Georgala A
Year : 2016
Journal : Belgian J Medical Oncology
Volume : 10(7)
Pages : 276-280

Do the Guidelines in Oncology Need to Evolve?

Authors : Awada A, Awada G, Hendlisz A
Year : 2016
Journal : Eur Med J
Volume : -
Pages : 15

Adjuvant endocrine therapy in preand perimenopausal women with breast cancer: practice guidelines

Authors : Duhoux F, Neven P, Awada A, Berlière M, Wildiers H, Denys H
Year : 2016
Journal : Belgian J Medical Oncology
Volume : 10(3)
Pages : 92-96

Dose-Seeking Phase I Trials for Currently Approved Molecular-Targeted Therapies in the USA: The Dose-Limiting Toxicity Definition Issue

Authors : Kotecki N, Awada A, Bonneterre J, Hebbar M, Adenis A, Cortot AB, Cousin C, Clisant S, Duhamel A, Penel N
Year : 2016
Journal : Pharmaceutical Medicine
Volume : 30(3)
Pages : 143-7

Eribulin in the soft tissue sarcoma therapeutic landscape: little is good, then more is better

Authors : Awada A, Penel N, Kotecki N
Year : 2016
Journal : TCR
Volume : 5(6)
Pages : s1160-62

Cancer immunotherapy: from the lab to clinical applications-Potential impact on cancer centres' organisation.

Authors : Cairns L, Aspeslagh S, Anichini A, Kyte JA, Blank C, Ascierto P, Rekers N, Straten PT, Awada A
Year : 2016
Journal : Ecancermedicalscience
Volume : 10
Pages : 691

Rôle de corticostéroïdes dans le cancer de la prostate. Effet bénéfique ou néfaste ?

Authors : Martinez C, Sideris S, Roumeguere T, Van Velthoven R, Awada A, Costante G, Gil T
Year : 2016
Journal : Onco-Hémato
Volume : -
Pages : -

Nutrition et prévention du cancer : changer les mentalités

Authors : Awada A
Year : 2016
Journal : Onco-Hémato
Volume : -
Pages : -

Foreword

Authors : Awada A
Year : 2016
Journal : EMJ Oncology
Volume : 41
Pages : 11

Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study.

Authors : Tolaney SM, Nechushtan H, Ron IG, Schöffski P, Awada A, Yasenchak CA, Laird AD, OKeeffe B, Shapiro GI, Winer EP
Year : 2016
Journal : Breast Cancer Res Treat
Volume : 160
Pages : 305-312

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016.

Authors : Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, Awada A, Banerjee S, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R, Coupland S, De Petris L, De Santis M, de Vries EG, Dizon DS, Duff J, Duska LR, Eniu A, Ernstoff M, Felip E, Fey MF, Gilbert J, Girard N, Glaudemans AW, Gopalan PK, Grothey A, Hahn SM, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones DV Jr, Jost L, Keilholz U, Khan S, Kiss A, Köhne CH, Kunstfeld R, Lenz HJ, Lichtman S, Licitra L, Lion T, Litière S, Liu L, Loehrer PJ, Markham MJ, Markman B, Mayerhoefer M, Meran JG, Michielin O, Moser EC, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K, Palumbo A, Peccatori FA, Pfeilstöcker M, Raut C, Remick SC, Robson M, Rutkowski P, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll HJ, Schnipper L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F, Strasser F, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber JS, Wildiers H, Yarden Y
Year : 2016
Journal : ESMO Open
Volume : 1
Pages : e000097

Phase I dose-escalation study of plitidepsin in combination with bevacizumab in patients with refractory solid tumors.

Authors : Aspeslagh S, Awada A, S Matos-Pita A, Aftimos P, Bahleda R, Varga A, Soria JC
Year : 2016
Journal : Anticancer Drugs
Volume : 27
Pages : 1021-7

Testicular germ cell tumor: Short and long-term side effects of treatment among survivors.

Authors : Gil T, Sideris S, Aoun F, Van Velthoven R, Sirtaine N, Paesmans M, Ameye L, Awada A, Devriendt D, Peltier A
Year : 2016
Journal : Mol Clin Oncol
Volume : 5
Pages : 258-264

Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer.

Authors : Ignatiadis M, Zardavas D, Lemort M, Wilke C, Vanderbeeken MC, Dhondt V, de Azambuja E, Gombos A, Lebrun F, Dal Lago L, Bustin F, Maetens M, Ameye L, Veys I, Michiels S, Paesmans M, Larsimont D, Sotiriou C, Nogaret JM, Piccart-Gebhart M, Awada A
Year : 2016
Journal : PLoS One
Volume : 11(7)
Pages : e0154009

Are virus-induced cancers more sensitive to checkpoint inhibitors?

Authors : Kanaan H, Kourie HR, Awada A
Year : 2016
Journal : Future Oncol
Volume : 12(23)
Pages : 2665-68

Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial. (Springerplus)

Authors : Cortés J, Rugo HS, Twelves C, Awada A, Perez EA, Im SA, Zhao C, Hoch U, Tomkinson D, Buchanan J, Tagliaferri M, Hannah A, OShaughnessy J
Year : 2016
Journal : Springerplus
Volume : 5
Pages : 1033

Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer.

Authors : Twelves C, Awada A, Cortes J, Yelle L, Velikova G, Olivo MS, Song J, Dutcus CE, Kaufman PA
Year : 2016
Journal : Breast Cancer (Auckl)
Volume : 10
Pages : 77-84